Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Relecom

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Gastrointestinal Tumors|May 13, 2021
Screening Status as a Determinant of Choice of Colorectal Cancer Screening Method: A Population-Based Informed SurveyJosé Luis Sandoval, Allan Relecom, Cyril Ducros, et al.
Journal of Translational Medicine|March 30, 2020
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapyAfsheen Raza, Maysaloun Merhi, Varghese Philipose Inchakalody, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 19, 2021
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexityAllan Relecom, Maysaloun Merhi, Varghese Inchakalody, et al.
International Journal of Environmental Research and Public Health|March 19, 2020
Resources-Stratified Guidelines for Classical Hodgkin LymphomaAllan Relecom, Massimo Federico, Joseph M Connors, et al.
Journal for Immunotherapy of Cancer|September 11, 2020
Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case reportMaysaloun Merhi, Afsheen Raza, Varghese Philipose Inchakalody, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Gastrointestinal Tumors|May 13, 2021
Screening Status as a Determinant of Choice of Colorectal Cancer Screening Method: A Population-Based Informed SurveyJosé Luis Sandoval, Allan Relecom, Cyril Ducros, et al.
Journal of Translational Medicine|March 30, 2020
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapyAfsheen Raza, Maysaloun Merhi, Varghese Philipose Inchakalody, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 19, 2021
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexityAllan Relecom, Maysaloun Merhi, Varghese Inchakalody, et al.
International Journal of Environmental Research and Public Health|March 19, 2020
Resources-Stratified Guidelines for Classical Hodgkin LymphomaAllan Relecom, Massimo Federico, Joseph M Connors, et al.
Journal for Immunotherapy of Cancer|September 11, 2020
Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case reportMaysaloun Merhi, Afsheen Raza, Varghese Philipose Inchakalody, et al.
Pageof 1